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In AIDS vaccine development the pendulum has swung towards a renewed emphasis on the potential role for neutralizing antibodies in a
successful global vaccine. It is recognized that vaccine-induced antibody performance, as assessed in the available neutralization assays, may well
serve as a “gatekeeper” for HIV-1 subunit vaccine prioritization and advancement. As a result, development of a standardized platform for
reproducible measurement of neutralizing antibodies has received considerable attention. Here we review current advancements in our knowledge
of the performance of different types of antibodies in a traditional primary cell neutralization assay and the newer, more standardized TZM-bl
reporter cell line assay. In light of recently revealed differences (see accompanying article) in the results obtained in these two neutralization
formats, parallel evaluation with both platforms should be contemplated as an interim solution until a better understanding of immune correlates of
protection is achieved.
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most effective strategy to combat viral diseases such as polio,
hepatitis, measles, and influenza. While antibodies are known
to play an important role in protection in these diseases, the
importance of antibodies in human immunodeficiency virus
type 1 (HIV-1) protection and pathogenesis remains to be further
defined (Huber and Trkola, 2007; McMichael, 2006; Srivastava⁎ Corresponding author. WRAIR, 13 Taft Court, Rockville, MD 20850, USA.
Fax: +301 762 4177.
E-mail address: vpolonis@hivresearch.org (V.R. Polonis).
0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2008.02.007et al., 2005; Zolla-Pazner, 2004). Despite this and because of
knowledge gained from other successful vaccines, the design of a
vaccine that will elicit antibody responses capable of neutralizing
primary isolates of multiple HIV clades continues to be an
important goal in laboratories that are developing and testing
vaccines. It has been proposed that, although the virus envelope
(Env) proteins have evolved an extraordinary ability to evade
neutralizing antibodies, a vaccine that can elicit protective
antibodies remains the best hope for developing an HIV vaccine
that confers sterilizing immunity. Vaccine strategies that
exclusively stimulate T-cell immunity may at best generate
316 Minireviewpersistent and broadly reactive T-cell responses that can suppress
virus and limit damage caused by the virus, without preventing
infection (McMichael, 2006). In light of recent developments in
HIV vaccine research (Cohen, 2007), humoral responses may be
a critical component of an efficacious product.
The challenge to develop an immunogen that elicits antibodies
effective against the genetically diverse strains of the HIV-1
pandemic is defined not only by the need to elucidate the
appropriate Env structure(s) and identify epitopes that induce
protective antibodies, but also by the requirement for standar-
dized in vitro assays that will allow for a meaningful comparison
of the quality and potency of neutralizing antibodies in sera or
other fluids fromHIV-positive patients and vaccine recipients. To
support the evaluation of phase I, II or I/II HIV vaccine clinical
trials that are being conducted to test new immunogens, it will be
important to utilize high throughput, validated neutralization
assays. In the context of analyzing new candidate vaccines or
newmonoclonal antibodies, the relevant in vitromeasurement of
neutralizing antibodies becomes a complex task, largely due to a
long list of confounding variables attributable to the virus, the
antibodies and the cells (Zolla-Pazner, 1996). Importantly, the
neutralization assay outcome may be determined by numerous
assay parameters. These variable parameters include: target cell
used and cell density, host cell used for viral stock propagation,
virus dose and antibody dilution/concentration (virus particle:
antibody ratio), the inclusion of complement, volumes of
components added, duration of pre-incubation of virus and
antibody, duration of infection with or without antibody, cell
washing steps to remove unbound antibody and virus, length of
culture time, the endpoint measured and other variables.
To address specific aspects of these variables, several
laboratories have produced panels of virologic and serologic
reagents from HIV-1-positive patients, drawn from multiple
geographic regions, to model some of the extensive genetic
variation of HIV-1. Neutralization platforms employing these
reagents have been evolving over two decades. In the majority of
neutralization assays, virus and antibody are incubated together
and then added to CD4+ target cells. The early neutralization
assays relied on the ability of T-cell line-adapted (TCLA) viruses
to infect cell lines; viral proteins, multinucleated giant cells
(syncytia), or cell survival could then be quantified to measure
reduction of infection. In general, neutralization of TCLAviruses
proved poorly predictive of primary isolate neutralization andwas
largely excluded as a “gatekeeper” assay. The critical concern
regarding the use of any cell line-based model system is its
physiologic relevance and value as a surrogate for in vivo
outcomes. Subsequently, assays were developed so that patient
viruses (primary or clinical isolates) could be used to infect HIV-
seronegative peripheral blood mononuclear cells (PBMC) from
healthy human donors, an approach thought to be more
physiologic. These primary cell target assays require the use of
donor PBMC from different individuals; the freshly isolated or
frozen PBMC are then stimulated with phytohemagglutinin
(PHA) and cultured with interleukin-2 (IL-2) before infection in
the presence or absence of test antibodies. It has long been known
that PBMC from different donors display differential suscept-
ibility to HIV-1 infection. These differences in HIV replicationmay be due, in part, to host genetics and CD8+ cell factors, the
number of CD4+ cells or expression levels of CD4 molecules on
host cells, effects of host cell-derived molecules on the viral
surface, and host genetic polymorphisms in chemokines or
chemokine receptors, such as CCR5, which function as HIV-1
coreceptors. Because of these variables, the inter-lab, and even the
inter-experiment variation within a single lab, is often quite
problematic in PBMC-based neutralization assays.
Prior to the development of PBMC assays, early efforts to
standardize and compare neutralization assays were initiated by
D'Souza et al. at the US NIH Division of AIDS, together with
investigators from the World Health Organization (WHO). A
large study (as part of the Antibody Serologic Project) was
conducted in 1990–91 by over 40 investigators from 25 orga-
nizations in 7 countries to compare assays for the evaluation of
HIV-1 monoclonal antibodies (mAbs). Later, a second mAb
study was performed comparing PBMC assays (D'Souza et al.,
1991; D'Souza et al., 1997).While considerable variations in the
protocols and the data were observed, these comparative studies
were very informative for the characterization of the potential
clinical utility of the mAbs tested. These studies were also
pioneering efforts directed towards the generation of standar-
dized approaches to neutralization assessment.
Recognizing that the issue of standardization of immunomo-
nitoring assays is critically important, several investigators from
a number of organizations around the world have subsequently
convened meetings and initiated studies to help identify and
reduce the variability across the assays currently in use. In 2003,
a meeting organized by WHO–UNAIDS was held in Milan,
Italy to discuss these issues. As a result of this meeting, a study
entitled NeutNet was initiated and funded through the European
Commission for HIV Vaccine Research. The NeutNet study was
conducted from 2005 to 2006 and involved international labo-
ratories from several countries. Employing a variety of assay
formats, study participants assessed four test reagents against a
panel of eleven HIV-1 isolates or a sub-panel of pseudoviruses.
While there was some degree of consistency in certain data
elements, there was also considerable variation in the results
observed (Scarlatti et al., manuscript in preparation).
In addition, in 2005, a standardized approach to the mea-
surement of neutralizing antibodies for vaccine trials was
proposed as a result of meetings convened by the Laboratory
Standardization Subcommittee for the Global HIV/AIDS
Vaccine Enterprise (GHAVE) (Mascola et al., 2005). This
standardization of approaches to monitor the function(s) of
vaccine-induced antibodies is reflected in the methodologies
currently being employed and investigated through the efforts of
the co-investigators of the “Comprehensive Antibody Vaccine
Immuno-Monitoring Consortium (CA-VIMC)”, centered at
Duke University Medical Center and funded by The Bill and
Melinda Gates Foundation in July of 2006. A global workshop,
entitled “Standardisation of HIV Neutralisation Assays for Use
in Vaccine Research and Clinical Trials”, was convened on
March 17–18, 2007 in Varese, Italy, by members of the WHO
and the European Commission for HIV Vaccine Research
(Meeting report in preparation). A recent summary meeting on
“Humoral Immune Responses to HIVand Approaches to Design
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Protective Antibodies” was also sponsored by the GHAVE in
Reston, VA, USA onMay 14–15, 2007 (Montefiori et al., 2007).
Thus, significant levels of effort and resources have now been
committed to the evaluation and implementation of platforms for
assessing vaccine-induced antibodies.
The newer technologic approaches exploit the use of
“pseudoviruses” that incorporate molecularly cloned HIV-1
Envs into defective virus particles capable of only a single
round of infection. The pseudoviruses are generated in the 293T
cell line by cotransfection of an env-mutated viral backbone,
along with the env clone of choice, and then used to infect a
transformed cell line expressing the appropriate receptors. One
such format is an assay that employs an epithelial HeLa-derived
cell line (TZM-bl) that carries the luciferase reporter gene
sensitive to the presence of the HIV Tat protein. This TZM-bl
assay has been advanced as a readily transferable method for
assessing vaccine-elicited neutralizing antibodies in the good
clinical laboratory practices (GCLP) environment. Table 1 shows
a comparison of several of the variable parameters (as described
above) that distinguish the PBMC assay from the pseudovirus
approach. The cell target, viral inocula, and culture conditions are
very different in the two assay systems. The pseudoviral system
has several advantages as a platform for application to front-line
assessment of antibodies, to include: the ability to rapidly test for
neutralization against primary patient Envs from multiple clades,
a high degree of inter-experiment reproducibility and throughput,
ease and safety of reagent distribution for the assay, and
facilitation of assay validation and global transfer (note Table 1).
However, specific discrepancies in the data obtained when
reporter cell line-based pseudovirus assays are compared with
PBMC-based assays, have recently been reported. Binley et al.
have demonstrated that the 4E10 gp41 mAb is broadly neutral-
izing in a pseudovirus system, but shows only moderate activity
in the PBMC assay. In contrast, in the same report it was shown
that the X5 gp120 mAb neutralizes considerably better in the
PBMC assay (Binley et al., 2004). A study by Choudhry et al.,
using the m46 gp41 mAb derived from an HIV+ patient with
broadly cross-neutralizing antibodies, clearly demonstrated
cross-clade neutralization in a PBMC assay, but no neutraliza-
tion in the pseudovirus platform (Choudhry et al., 2007).
Neutralization data are presented in Table 2 showing results
using antibodies, screened at 30 μg/ml (mAbs) or at a 1:40Table 1
Comparison of HIV neutralization assay parameters
Assay PBMC TZM-bl (JC53-bl)
Cells PBMC Epithelial HeLa
Virus Uncloned primary Pseudovirus
Assay length 4–6 days 2–3 days
Common endpoint Extra- or intra-cellular p24 Luciferase activity
Rounds of infection Either multiple or single Single only
DEAE-dextran used? No Yes
Measure inhibition of:
Attachment/entry Yes Yes
Cell–cell transmission Potentially No
Coreceptors used CCR5, CXCR4, others
(CCR5 physiologic)
CCR5, CXCR4 (N2 logs
more CCR5 than PBMC)dilution (USHIV+ pool), against 30 viruses representing six
major clades (Brown et al., 2005). The antibodies were tested in
a PBMC assay against primary isolates, or in the TZM-bl assay
against a pseudovirus prepared from the matched primary
isolate. Red boxes indicate the positive results and the negative
values are highlighted in blue, using 50% neutralization as a cut-
off (Brown et al., 2005). It can be seen that the m9 anti-gp120
single chain mAb and the m47 anti-gp41 mAb (M. Zhang et al.,
in preparation) both appear to show better neutralization in the
PBMC system as compared to the TZM-bl assay. However, as
previously shown by Binley et al. (2004), the 4E10 mAb
displays much broader neutralizing activity in the pseudovirus
assay, neutralizing 29/30 pseudoviruses as compared to 13/30
primary isolates in the PBMC assay. As might be expected, the
2F5 mAb does not neutralize clade C viruses, in which the target
epitope is absent, in either assay (Table 2).
A recent study of an anti-phosphatidyl inositol phosphate
(PIP) mAb has suggested that targeting lipids in close proximity
to the viral and/or host cell membrane during viral fusion and
entry, may be sufficient to neutralize HIV-1. The anti-PIP mAb
appears to neutralize the virus only in assays where PBMC are
used as target cells, and not at all in the TZM-bl cell line-based
pseudovirus assay (Brown et al., 2007). Additional information
regarding the activity of anti-lipid mAbs derived from humans
with anti-phospholipid antibody syndrome and systemic lupus
erythematosus has also recently been presented. A subset of
these antibodies, which recognize a variety of lipids (Alam
et al., 2007), have been shown to neutralize primary isolates in a
PBMC assay, but not the matched pseudoviruses in the TZM-bl
platform (B Haynes, personal communication). This finding is
similar to the observation using the PIP anti-lipid mAb.
It has been recognized that some investigators in the field of
HIV vaccine research and development have perceived these
two neutralization assay formats to be interchangeable in the
data that they provide. Taking into account that there are several
differences between the individual parameters of the two
neutralization platforms (Table 1), we sought to compare a
primary PBMC format to the TZM-bl pseudovirus assay,
in “totality” and as they are currently performed, using a large
panel of sequenced viruses from patients in the chronic stages of
infection and polyclonal plasma pools. The pools were comprised
of 6–10 pure clade plasmas from HIV-1-seropositive individuals
from 6 different countries, each with a different predominant
circulating HIV-1 clade. These plasma pools were tested against a
panel of 60 primary isolates (10 each from 6 major clades A–D,
CRF01_AE and CRF02_AG), in a PBMC assay using reduction
of supernatant p24 as an endpoint. Pseudoviruses prepared from a
single env clone representing 56 of the 60 virus isolates, were then
tested using the same 6 plasma pools in the TZM-bl cell assay.
The virus–antibody pairs showing≥50% neutralization at a 1:40
plasma dilution were further evaluated to obtain 50% and 80%
endpoint titers, and the reciprocal titer values from the two
neutralization assays were compared by linear regression.
Fig. 1 shows the comparison of the 336 plasma/virus pairs in
the two assays. No direct correlation was observed (R2 =0.002,
Fig. 1A). Overall, there was 60% concordance in qualitative
neutralizing activity measured by both assays. Within the
Fig. 1. (A) A comparison of 50% endpoint titers from the PBMC and TZM-bl
assays using 56 primary viruses or 56 corresponding pseudoviruses neutralized
using 6 clade-specific plasma pools. To allow the use of a log scale, all weak
titers (b40) were arbitrarily assigned the value of 1.0. Linear regression
(R2=0.002) shows no direct correlation in the values observed. (B) The
proportion (%) of titers for virus/plasma pairs which are positive only in the
PBMC or TZM-bl assays, or concordant positive or negative in both assays.
Table 2
Comparison of neutralization data from PBMC versus TZM-bl assays using a
single antibody concentration of 30 μg/ml (mAbs) or a 1:40 dilution (USHIV+
pool)
Five different antibody sources were tested for neutralization (≥50%, indicated
by red boxes) of 30 primary isolates in a PBMC assay or 30 pseudoviruses
(derived from the corresponding strains) in the TZM-bl assay. The m9 is a single
chain anti-gp120 mAb and m47, 2F5, and 4E10 are gp41 mAbs, while USHIV+
is a pool of sera from N. American HIV-positive patients.
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13% were concordant positive (Fig. 1B), in agreement with
commonly observed neutralization resistance of primary isolate
Envs. The remaining 40% of the paired titers were positive in
one assay, and negative in the other. Of these pairs, 23% were
positive only in the TZM-bl and 17% only in the PBMC assay.
Thus, assay discordance was bi-directional and not attributable
to assay sensitivity. The 80% reciprocal neutralization titers also
showed no direct correlation (R2 =0.004, data not shown).
Using a panel of pseudoviruses prepared with clade B and C
envelopes from acute and early infection, we have seen a similar
discrepancy among 31 plasma/virus pairs tested in both assays
(R2 =0.05). In this smaller data set with acute/early samples, a
61% concordance was found in the qualitative neutralization
between the two assays (data not shown).
Identification of the mechanisms underlying the significant
differences observed between these two assay formats will be
important andmay require examination of the biologic parameters
at play in both assays. The assays in which primary cells are used
have been proposed tomore closely resemble the in vivo host cells
for HIV, although mitogen-stimulated lymphoblasts are not
typical of tissue or circulating T cells. Assays employing primary
cells typically capture all stages of the virus life cycle during
neutralization assays incorporating multiple rounds of infection.
The TZM-bl assay is a single round assay and primarily assesses
inhibition of virus binding and entry. It is possible that some
antibody subpopulations may not be detected through the use of a
single assay focusing only on virus entry. Another fundamental
difference between T cells and the HeLa-derived TZM-bl cells
may lie in the location of HIV/receptor interaction(s). The
majority of HIV-1 entry into T cells occurs at the plasma
membrane via CD4 and chemokine receptor-mediated engage-
ment and fusion. In HeLa cells, endocytosis has been reported to
account for approximately 85% of virus entry (Marechal et al.,1998). Moreover, TZM-bl assays often include the use of DEAE-
dextran during the infection phase. If endocytosis is playing a
significant role in viral entry in TZM-bl cells, this compoundmost
likely enhances productive infection by buffering endosomes,
thus allowing the pseudovirus to avoid lysosomal degradation and
to enter the cell through the endosomal vesicle.
Data from our laboratory and others also suggest that certain
cell line models, ie. TZM-bl cells, express vastly different levels
of the cell surface coreceptor CCR5, compared to primary
PBMC (Table 1). The CD4 receptor expression on the two cell
types is relatively similar, but there appears to be about 100-fold
more CCR5 on TZM-bl cells than on either activated or non-
activated PBMC. The CD4:CCR5 ratio may actually be more
important to the kinetics of virus entry than simply the increased
level of CCR5 on the TZM-bl and other cell lines. While the
CD4:CCR5 ratio on TZM-bl cells is approximately 2, this same
ratio is about 20, on average, for PHA-stimulated PBMC (Rosa
Borges et al., submitted for publication). These cell surface
differences may significantly alter measurements of virus–
antibody–host cell interactions and kinetics, as has recently
been shown using the X5 gp120 mAb (Choudhry et al., 2006).
The difference in the efficacy of neutralization by the X5 mAb
319Minireviewin cells with reduced CCR5 expression underscores the role of
the cell substrate in HIV neutralization assays.
The mechanism by which neutralizing antibodies function
also may influence how well the neutralization results obtained
in the two platforms correlate. In the study by Binley et al., the
results using the potently neutralizing mAb IgG1 b12 (b12)
correlated well between the two assays (84%), while the mAb
4E10 showed only 52% concordance between the two assays
(Binley et al., 2004). It is believed that CD4 engagement is the
first step of HIV-1 infection, allowing the virus to recognize its
target cell. The b12 mAb is thought to neutralize by binding to
the CD4 binding site in gp120 and stopping the engagement of
gp120 and CD4 on the cell surface. Blockage of CD4
engagement has been shown to halt both plasma membrane
fusion as well as entry into the cell through endocytosis in
epithelial cells (Schaeffer et al., 2004); concordance in the two
assays may reflect inhibition of an early event of HIVentry into
primary cells and cell lines alike. While the mechanism of
neutralization by 4E10 is unknown, it has been shown that this
mAb loses the ability to bind to the membrane proximal external
region of gp41 (MPER) as the level of fusion increases. The
inhibition of infection by 4E10 follows a similar time course to
that of C34, a peptide that blocks virion Env fusion with the cell
membrane (Dimitrov et al., 2007). If endocytosis is the major
route of virus entry into TZM-bl cells, it is possible that the
process of viral entry through the endosome results in extended
(or otherwise altered) exposure of the MPER, thus allowing
4E10 to more effectively neutralize the virus in TZM-bl assays.
Despite the differences in the data described herein (Table 2
and Fig. 1), without a measurable humoral immune correlate of
protection fromHIV-1 infection or viremic control as established
in a clinical setting, it is impossible to predict which assay may
better quantify protective neutralization. Thus, to better under-
stand the differences between the assays, research should focus
on understanding the results in which the neutralizing antibody–
virus pairs show discordant results between the two assays.
Additionally, it may be valuable to study how the TZM-bl assay
could be altered such that the parameters would more closely
represent the physiologic state. This could include using TZM-bl
clones or different reporter cell clones that express CCR5 at
levels comparable to those levels measured on primary in vivo
target cells (ie. lymphocytes and monocyte–macrophages). The
293Tcell clones used to produce the pseudoviruses could also be
modified to express more common host factors that HIV
particles incorporate while budding from primary host cells.
These host cell molecules include such major immune system
proteins as ICAMs,MHC class I andMHC class II (Cantin et al.,
2005). Another approach to achieve parity between the two
platforms involves using hybrid assays wherein pseudoviruses
are used as viral inocula for PBMC target cells and primary
isolates are used to infect TZM-bl cells. Studies such as these are
currently underway in several laboratories and will help provide
insight into the possible underlying mechanisms that influence
the differences observed between these two assays.
Functional assays using PBMC from different HIV-negative
donors may also be impacted significantly by variations in the
viral stocks. Viruses isolated from the plasma or cells of HIV-1-positive individuals on PHA-activated, donor PBMC represent a
quasispecies, comprised of related but non-identical sequences.
With serial passage on different PBMC, perturbations in the
composition of the quasispecies can occur. Thus, virus stocks
isolated on primary PMBC are impermanent, non-standardizable,
and difficult to precisely define in terms of nucleotide sequence(s).
Nevertheless, viruses isolated and propagated on primary
PBMC are considered to most closely represent those circu-
lating in vivo. In contrast, viruses adapted to growth in T-cell lines,
and those produced in cell lines by transfection of infectious
molecular clones (IMC), have altered neutralization susceptibility
compared to PBMC-derived viruses (Louder et al., 2005). In
addition, the pseudoviruses prepared using an env clone that
represents only one of the possible quasispecies present in clinical
isolates may or may not reflect the neutralization sensitivity of the
quasispecies population from which the env clone was derived.
The preparation of IMC (with the env clone or clones of choice
incorporated) that could be passaged once in PBMC may prove
useful for assessing the role of env diversity and host cell
molecules in neutralization. Systematic comparisons of viral
quasispecies, viral stocks of defined sequence produced in cell
lines or primary PBMC, and pseudoviruses with corresponding
Envs may also shed light on the reasons for the current
discrepancies that have been reported between assays.
Significant challenges remain for the development of a
global vaccine for HIV. Foremost amongst these challenges is
the identification, in a clinical setting, of assay platform(s) that
will best provide predictive value with regard to protection of
humans against HIV infection and spread. The performance of
passive antibody transfer and protection studies in animal
models, followed by assessment of the sera from these studies in
current neutralization assay platforms, may help to determine
which assay has greater correlative value. In the current absence
of a “gold standard” for comparative vaccine studies, it is
important to consider exactly what processes or parameters are
being measured in each type of neutralization assay. Effective
inhibition of HIV-1 entry may require different neutralizing
antibody species, depending on the target cell. Although there
seem to be identifiable disparities between neutralization
profiles obtained using TZM-bl vs. PBMC assays, it is presently
unclear what the relative contribution of either assay will be
toward elucidating the correlates of neutralization susceptibility,
and toward selecting the best candidate vaccine. Evaluation of
antibodies in different assay platforms, reflecting the biologic
variation in the interaction of HIV-1 with its target cells in vivo,
should be contemplated as an interim solution to this problem.
The TZM-bl assay, through a significant level of multi-
national effort and commitment of resources, has undergone
substantial development and should be maintained as a widely
applied, validated standard platform for HIV-1 vaccine devel-
opment. The field should also acknowledge that further
standardization of the PBMC assay has lagged and take steps
to readdress this deficiency. The recent international conference
convened by the WHO and NeutNet Working Group (March
17–18, 2007, Varese, Italy) highlighted the significant amount
of ground to be covered before the PBMC assay achieves a level
of consistency, reproducibility, and portability. Systematic
320 Minireviewstudies directed at reducing the variability within PBMC assays
will be important in making progress towards standardization.
Manipulation of the pseudovirus assay to more closely reflect
physiologic parameters is a second approach that is currently
being pursued in several laboratories. The results from studies
within NeutNet and the GHAVE CA-VIMC will be a key in
advancing our ability to identify differences between neutrali-
zation assays, either PBMC or reporter cell line-based. Indeed,
the NeutNet study, while using smaller panels of reagents, will
be able to address differences between multiple PBMC assays,
as well as reporter cell line assays. The continuation of these
studies, combined with the efforts and collaborations of mul-
tiple organizations, will provide insight into the inter-lab
variability that occurs within and between assay systems.
Finally, more detailed studies should and will be performed
to compare platforms, as these studies may further reveal assay
parameters or antibody properties that result in higher or lower
degrees of concordance between different formats. These com-
bined approaches will facilitate optimal progress towards the
critical goal of achieving vaccine-elicited, broadly protective
neutralizing antibodies.
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